TCG Labs Soleil, a venture capital and biotech R&D operator, announced a $400 million funding round to accelerate the launch and development of its portfolio of single-asset biotechnology startups. Founded in collaboration with The Column Group, the firm focuses on building narrowly targeted drug development companies optimized for capital efficiency. With this new financing, TCG Labs Soleil expands its operational hub to Shanghai alongside its original center in San Francisco. The company currently manages 10 portfolio biotechs targeting diseases such as cancer, immune disorders, and cardiometabolic conditions. Named leadership includes Jin-Long Chen, known for his former leadership roles at NGM Biopharmaceuticals and Amgen. The fresh capital reflects progress toward clinical milestones and aims to catalyze strategic partnerships or in-house development.